Levofloxacin ophthalmic solution

Mice were anaesthetised with three types of mixed anaesthetic agents by intraperitoneal injection. A mixed anaesthetic was prepared with 0.75 mg/kg medetomidine, 4.0 mg/kg midazolam, and 5.0 mg/kg butorphanol. In addition, the cornea was anaesthetised with 0.4% oxybuprocaine hydrochloride ophthalmic solution (Santen; Benoxil). 10 μg of bosentan monohydrate (Tokyo Chemical Industry; B5118; in DMSO), 1 μg of human IGF1 (PeproTech; AF-100-11; in PBS), or 10⁹ genome copies of AAV were prepared alone or in mixtures and were introduced as 1 μl into the vitreous body of both eyes of each animal with a 35 G needle (Saito Medical Instruments). After AAV treatment, 0.5% levofloxacin ophthalmic solution (Santen; Cravit) was applied to the ocular surface to prevent infection, and 0.75 mg/kg atipamezole was intraperitoneally injected to reverse anaesthesia.

Mice were anaesthetised with three types of mixed anaesthetic agents by intraperitoneal injection. A mixed anaesthetic was prepared with 0.75 mg/kg medetomidine, 4.0 mg/kg midazolam, and 5.0 mg/kg butorphanol. In addition, the cornea was anaesthetised with 0.4% oxybuprocaine hydrochloride ophthalmic solution (Santen; Benoxil). 10 μg of bosentan monohydrate (Tokyo Chemical Industry; B5118; in DMSO), 1 μg of human IGF1 (PeproTech; AF-100-11; in PBS), or 10⁹ genome copies of AAV were prepared alone or in mixtures and were introduced as 1 μl into the vitreous body of both eyes of each animal with a 35 G needle (Saito Medical Instruments). After AAV treatment, 0.5% levofloxacin ophthalmic solution (Santen; Cravit) was applied to the ocular surface to prevent infection, and 0.75 mg/kg atipamezole was intraperitoneally injected to reverse anaesthesia.